company background image
SRGA

Surgalign HoldingsNasdaqGS:SRGA Stock Report

Market Cap

US$183.4m

7D

-5.1%

1Y

-31.8%

Updated

24 Sep, 2021

Data

Company Financials +
SRGA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SRGA Overview

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide.

Surgalign Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Surgalign Holdings
Historical stock prices
Current Share PriceUS$1.31
52 Week HighUS$0.88
52 Week LowUS$3.27
Beta2.17
1 Month Change-2.24%
3 Month Change-7.09%
1 Year Change-31.77%
3 Year Change-70.89%
5 Year Change-58.15%
Change since IPO-90.68%

Recent News & Updates

Shareholder Returns

SRGAUS Medical EquipmentUS Market
7D-5.1%-0.2%-0.5%
1Y-31.8%40.4%37.5%

Return vs Industry: SRGA underperformed the US Medical Equipment industry which returned 40.4% over the past year.

Return vs Market: SRGA underperformed the US Market which returned 37.5% over the past year.

Price Volatility

Is SRGA's price volatile compared to industry and market?
SRGA volatility
SRGA Beta2.17
Industry Beta0.88
Market Beta1

Stable Share Price: SRGA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SRGA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1997197Terry Richhttps://www.surgalign.com

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability.

Surgalign Holdings Fundamentals Summary

How do Surgalign Holdings's earnings and revenue compare to its market cap?
SRGA fundamental statistics
Market CapUS$183.42m
Earnings (TTM)-US$173.12m
Revenue (TTM)US$102.24m

1.8x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRGA income statement (TTM)
RevenueUS$102.24m
Cost of RevenueUS$35.73m
Gross ProfitUS$66.51m
ExpensesUS$239.63m
Earnings-US$173.12m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin65.05%
Net Profit Margin-169.33%
Debt/Equity Ratio0%

How did SRGA perform over the long term?

See historical performance and comparison

Valuation

Is Surgalign Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SRGA ($1.31) is trading below our estimate of fair value ($9.45)

Significantly Below Fair Value: SRGA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SRGA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SRGA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRGA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRGA is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (4.8x).


Future Growth

How is Surgalign Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

39.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRGA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SRGA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SRGA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SRGA's revenue (13.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: SRGA's revenue (13.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SRGA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Surgalign Holdings performed over the past 5 years?

-62.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRGA is currently unprofitable.

Growing Profit Margin: SRGA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRGA is unprofitable, and losses have increased over the past 5 years at a rate of 62.9% per year.

Accelerating Growth: Unable to compare SRGA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRGA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).


Return on Equity

High ROE: SRGA has a negative Return on Equity (-327.8%), as it is currently unprofitable.


Financial Health

How is Surgalign Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SRGA's short term assets ($149.6M) exceed its short term liabilities ($52.8M).

Long Term Liabilities: SRGA's short term assets ($149.6M) exceed its long term liabilities ($64.2M).


Debt to Equity History and Analysis

Debt Level: SRGA is debt free.

Reducing Debt: SRGA has no debt compared to 5 years ago when its debt to equity ratio was 32.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRGA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SRGA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Surgalign Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRGA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRGA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRGA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Terry Rich (53 yo)

1.17yrs

Tenure

US$1,722,414

Compensation

Mr. Terry M. Rich has been President, Chief Executive Officer and Director of Surgalign Holdings, Inc. since July 2020. He joined Surgalign in November 2019. He was President of Global Spine at Surgalign H...


CEO Compensation Analysis

Compensation vs Market: Terry's total compensation ($USD1.72M) is above average for companies of similar size in the US market ($USD1.09M).

Compensation vs Earnings: Insufficient data to compare Terry's compensation with company performance.


Leadership Team

Experienced Management: SRGA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: SRGA's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SRGA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.9%.


Top Shareholders

Company Information

Surgalign Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Surgalign Holdings, Inc.
  • Ticker: SRGA
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$183.420m
  • Shares outstanding: 137.91m
  • Website: https://www.surgalign.com

Number of Employees


Location

  • Surgalign Holdings, Inc.
  • 520 Lake Cook Road
  • Suite 315
  • Deerfield
  • Illinois
  • 60015
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/24 22:20
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.